MedDataX Logo

Epidemiology of Community Acquired Pneumonia in North Israel

NCT ID: NCT00390819

Last Updated: 2006-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality.

CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential.

Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment.

Material \& Methods:

We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant.

In addition to demographic and clinical data, following tests will be performed:

1. Blood cultures
2. Sputum
3. PCR - throat culture to the following pathogens:

* Mycoplasma pneumoniae
* Chlamydia pneumoniae
* Legionella
* Adenovirus
* Influenza A
* Influenza B
* RSV
* Metapneumovirus
* Parainfluenza
* Pneumococcal antigen in urine

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Acquired Pneumonia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Community acquired pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Community acquired pneumonia
* Hospitalization

Exclusion Criteria

* Immunocompromised patients
* Patients under chemotherapy treatment
* Patients under steroids treament
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HaEmek Medical Center, Israel

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fahmi Shibli, M.D.

Role: PRINCIPAL_INVESTIGATOR

Ha'Emek Medical Center, Afula, Israel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ha'Emek Medical Center

Afula, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fahmi Shibli, M.D.

Role: CONTACT

Phone: 972-4-6494000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fahmi Shibli, M.D.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Porath A, Schlaeffer F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect. 1997 Jan;34(1):41-8. doi: 10.1016/s0163-4453(97)80008-4.

Reference Type BACKGROUND
PMID: 9120323 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

131074

Identifier Type: -

Identifier Source: org_study_id